Sugi Predict

Sugi Predict / Compounds / SCHEMBL6094315

SCHEMBL6094315

SCHEMBL6094315

Oc1ccc(N2[CH]CNCC2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ QDPR P09417 1/20 0.39
▸ ESR1 P03372 2/20 0.37
▸ ESRRG P62508 2/20 0.37
▸ ESRRB O95718 1/20 0.36
▸ PIM1 P11309 3/20 0.35
▸ PIM3 Q86V86 3/20 0.35
▸ PIM2 Q9P1W9 3/20 0.35
▸ FGFR1 P11362 1/20 0.35
▸ FGFR2 P21802 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ PKM P14618 1/20 0.34
▸ ADRB1 P08588 3/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ ADRB2 P07550 1/20 0.33
▸ NCF1 P14598 1/20 0.33
▸ PLD1 Q13393 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4094720 0.81 HTR7 (0.39) KDM4EALDH1A1MAPTADRB1HTR3A
SCHEMBL3483001 0.81 ADRB1 (0.55) MAPTADRB1HTR3EHTR3BHTR3A
SCHEMBL6645954 0.81 ADRB1 (0.55) ESRRGESRRBALDH1A1MAPTADRB1
SCHEMBL739058 0.80 SIGMAR1 (0.52) ALDH1A1ADRB1KMT2AMEN1ADRB2
SCHEMBL3537094 0.78 PLD1 (0.57) ALDH1A1ADRB2NCF1PLD1CHRNB2
SCHEMBL6956749 0.78 KDM4E (0.43) KDM4E
SCHEMBL6094131 0.78 ALDH1A1 (0.47) ALDH1A1MAPTKMT2AMEN1
SCHEMBL2410875 0.77 ADRB1 (0.59) ADRB1HTR3EHTR3BHTR3AHTR3D
SCHEMBL3482360 0.73 ADRB1 (0.59) KDM4EALDH1A1MAPTADRB1KMT2A
SCHEMBL3482596 0.73 ADRB1 (0.59) KDM4EALDH1A1MAPTADRB1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7030150-B2 Benzimidazole compounds and antiviral uses thereof TRIMERIS, INC. 2006-04-18 — — US claimed
US-20030119754-A1 Benzimidazole compounds and antiviral uses thereof TRIMERIS, INC. 2003-06-26 — — US claimed
WO-2002092575-A1 BENZIMIDAZOLE COMPOUNDS AND ANTIVIRAL USES THEREOF TRIMERIS, INC. (US) 2002-11-21 — — WO claimed
US-20060142365-A1 Benzimidazole compounds and antiviral uses thereof TRIMERIS, INC. 2006-06-29 — — US disclosed
US-7030150-B2 Benzimidazole compounds and antiviral uses thereof TRIMERIS, INC. 2006-04-18 — — US disclosed
US-20030119754-A1 Benzimidazole compounds and antiviral uses thereof TRIMERIS, INC. 2003-06-26 — — US disclosed
WO-2002092575-A1 BENZIMIDAZOLE COMPOUNDS AND ANTIVIRAL USES THEREOF TRIMERIS, INC. (US) 2002-11-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142365-A1 Benzimidazole compounds and antiviral uses thereof MAVS, ZC3HAV1, TIMM13 QDPR 2235/4885ESR1 2638/4885ESRRG 4353/4885
US-20030119754-A1 Benzimidazole compounds and antiviral uses thereof MAVS, ZC3HAV1, TIMM13 QDPR 2235/4885ESR1 2638/4885ESRRG 4353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.